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Musgrove Park Hospital,  Taunton , UK 
change significantly with therapeutic CPAP (from 29.1  8 
14.7 to 30.2  8 13.6 IU/l), nor with sub-therapeutic CPAP 
(from 28.2  8 16.2 to 29.5  8 12.6 IU/l; difference between 
mean changes –0.2, 95% CI –3.0 to 2.6 IU/l, p = 0.87 between 
groups).  Conclusions: Four weeks of active CPAP has no ben-
eficial effect on aminotransferase levels when compared to 
sub-therapeutic CPAP in patients with OSAS. Therefore, 
CPAP does not seem to improve biochemical markers of po-
tential NAFLD in OSAS patients. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 The obstructive sleep apnoea syndrome (OSAS) is 
characterized by repetitive apnoeas/hypopnoeas during 
sleep, which are associated with oxygen desaturation and 
sleep disruption. It has been estimated that between 2 and 
4% of the adults in western countries suffer from clin-
ically significant OSAS, and it is becoming more preva-
lent as the average body weight increases in these popula-
tions  [1] .
 OSAS has been associated with features of the meta-
bolic syndrome, including obesity  [2] , hypertension  [3] , 
dyslipidaemia  [4] and insulin resistance  [5] , some of 
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 Abstract 
 Background: Obstructive sleep apnoea syndrome (OSAS) 
has been suggested to be an independent risk factor for 
non-alcoholic fatty liver disease (NAFLD), possibly via inter-
mittent hypoxia that influences blood pressure, lipid levels 
and insulin resistance, factors themselves known to cause 
NAFLD. In observational studies, OSAS has been associated 
with elevated levels of liver enzymes. Continuous positive 
airway pressure (CPAP) is the treatment for OSAS, but the ef-
fects of CPAP on liver enzymes have not been studied in a 
randomized controlled trial.  Objective: To determine if 4 
weeks of CPAP influence alanine-aminotransferase (ALT) 
and aspartate-aminotranferase (AST) levels.  Methods: 94 
patients with moderate-to-severe OSAS were randomized 
to therapeutic or sub-therapeutic CPAP treatment. Plasma 
ALT and AST were measured before and after 4 weeks of 
CPAP.  Results: Results are means  8 SD. ALT levels de-
creased from 39.1  8 26.3 to 30.3  8 16.4 IU/l in patients treat-
ed with therapeutic CPAP, but also decreased from 36.9  8 
20.7 to 31.5  8 16.5 IU/l in patients treated with sub-thera-
peutic CPAP (difference between mean changes –3.4, 95% CI 
–7.8 to 1.0 IU/l, p = 0.13 between groups). AST levels did not 
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which are also thought to contribute to the pathogenesis 
of non-alcoholic fatty liver disease (NAFLD)  [6, 7] . Data 
from recently published cross-sectional and prospective 
studies have implied that repetitive episodes of hypoxia 
occurring during sleep in patients with OSAS are an ad-
ditional causal factor in the development of NAFLD, 
which is independent from obesity and the metabolic 
syndrome  [8] . Furthermore, uncontrolled treatment 
studies of adults and children with OSAS with continu-
ous positive airway pressure (CPAP) and tonsillectomy, 
respectively, were associated with a lowering of liver
enzyme levels, suggesting that CPAP might improve 
NAFLD in patients with OSAS  [9, 10] .
 However, there are no data from randomized con-
trolled studies proving that CPAP treatment has a benefi-
cial effect on liver function. To address this uncertainty, 
we analysed stored blood samples from a large-scale ran-
domized controlled trial of CPAP versus sub-therapeutic 
CPAP in order to investigate the effects of active treat-
ment on liver enzymes in patients with symptomatic 
OSAS.
 Methods 
 Patients 
 Patients with possible OSAS were referred to the Oxford Sleep 
Unit, Oxford Centre for Respiratory Medicine, UK by general 
practitioners, ear, nose and throat surgeons or other hospital con-
sultants. Patients were eligible for the trial if they were males aged 
between 20 and 75 years who had excessive daytime sleepiness 
(Epworth Sleepiness Scale score  6 10) and proven OSAS with  1 10 
oxygen desaturations of  1 4% per hour (oxygen desaturation in-
dex, ODI,  1 10/h). All eligible patients were offered participation 
in the study, unless they required urgent CPAP therapy because 
of respiratory failure, driving or employment issues. None of the 
patients had a medical history of a liver disease. The study was 
approved by the Oxford research ethics committee, and written 
informed consent was obtained from all participants. Data on 
blood pressure from 52 of these patients had been presented in a 
previously published study evaluating the effect of CPAP on am-
bulatory blood pressure  [3] .
 Sleep Study, CPAP and Assessment of Sleepiness 
 OSAS was diagnosed from 1-night, in-hospital, pulse oxime-
try and ECG, combined with continuous video recordings. Pa-
tients’ body movements, heart rates and pulse transit time chang-
es were recorded as measures of arousal from sleep. Pulse oxim-
etry, snoring and increases in the respiratory swing in pulse 
transit time were used as markers of breathing pattern and respi-
ratory effort (Win-Visi monitoring system, Stowood Scientific In-
struments, Oxford, UK) as previously described and validated 
 [11, 12] . The results of the sleep study were scored automatically, 
with manual review to ensure accuracy of the data. OSAS was di-
agnosed from a review of all the data and a clinical interview, and 
the severity was quantified as the number of oxygen desaturations 
 1 4% per hour of study (the ODI). 
 After enrolment, patients were randomly assigned to either 
therapeutic or sub-therapeutic CPAP, and they then underwent 
a second sleep study, during which respiratory polysomnogra-
phy was repeated and CPAP was used according to the assigned 
group. For patients assigned to therapeutic CPAP, the therapeu-
tic pressure was determined from overnight use of the Sullivan 
Autoset-T auto-adjusting CPAP machine (ResMed, Abingdon, 
UK), from which mask pressure was recorded and synchronized 
with the sleep study signals. The record was reviewed the next 
morning, and the optimum pressure to prevent sleep apnoea, 
usually the 95th percentile of pressure overnight, was confirmed 
by a sleep technician. Patients assigned to sub-therapeutic CPAP 
used a machine that delivered  ! 1 cm H 2 O pressure, as previ-
ously described  [3] , which is insufficient to hold the pharynx 
open  [13] .
 Patients were blind to whether they were receiving therapeutic 
or sub-therapeutic CPAP, and so were the investigators. The sleep 
nurse who randomly assigned patients to the 2 groups, main-
tained the machines and assisted the patients was not involved in 
outcome assessments.
 Subjective sleepiness was assessed using the Epworth Sleepi-
ness Scale, which assesses the tendency to fall asleep during 8 
typical daytime situations  [14] . Objective sleepiness was mea-
sured with 1 sleep resistance challenge (Osler test), which tests the 
ability to stay awake in a darkened and sound isolated room. This 
was carried out at the same time of day on the 2 occasions each 
patient was studied  [15] .
 Liver Enzymes 
 Measurements of alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) were performed on plasma samples 
which were stored at –80 ° C. ALT and AST were measured in pairs 
of baseline/follow-up samples, using a standard automated enzy-
matic assay (ADVIA 2400, Siemens, Frimley Park, UK) as previ-
ously described  [16, 17] . Method precision, expressed as the % 
coefficient of variation, was 3.6% at 30 IU/l and 2.5% at 140 IU/l 
for AST, and 3.9% at 42 IU/l and 2.8% at 140 IU/l for ALT.
 Follow-Up 
 After baseline assessments, patients used their therapeutic or 
sub-therapeutic CPAP machine (Sullivan 6, ResMed, Abingdon, 
UK) for 4 weeks and then returned to the treatment centre for re-
peat measurements. Hour meters on the CPAP machines were 
downloaded to calculate mean nightly use. At the end of the trial, 
CPAP pressure was retitrated in every patient to establish their 
therapeutic pressure for subsequent long-term use.
 Data Analysis 
 Data are expressed as mean  8 SD unless otherwise stated in 
the text. All statistical analyses were performed with Statistica 
v6.0 (StatSoft, Tulsa, Okla., USA). Differences between and with-
in the groups at baseline and after 4 weeks were assessed by un-
paired and paired t tests as appropriate. Differences between the 
changes seen in each group are expressed as the mean and 95% 
CIs, therapeutic minus sub-therapeutic. Data were analysed on an 
intention-to-treat basis, with no change assumed when follow-up 
liver enzyme data were missing. Data were also analysed as per 
the protocol (with no data assumption, thus including only those 
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subjects with complete follow-up data) to assess whether this dif-
fered from the intention-to-treat analysis. For comparison of fre-
quencies, the   2 test of independence was used. Spearman’s rank 
test was used for correlation analysis. p  ! 0.05 was considered to 
be statistically significant.
 Results 
 Patients Characteristics 
 Of the 102 patients in the original trial, 94 patients 
with a mean age of 48.3  8 9.9 years had stored blood 
samples. Of these patients, 47 were randomized to thera-
peutic and 47 to sub-therapeutic CPAP. The 2 groups 
were similar regarding age, body mass index (BMI), fat 
distribution, alcohol consumption, smoking status, fre-
quency of hypertension (and antihypertensive medica-
tion) and severity of sleep apnoea ( table 1 ). 
 Liver Enzymes 
 Blood samples from 94 patients were available for 
analysis at baseline, and from 87 at follow-up (44 in the 
therapeutic and 43 in the sub-therapeutic group). ALT 
levels decreased from 39.1  8 26.3 to 30.3  8 16.4 IU/l in 
patients treated with therapeutic CPAP for 4 weeks, but 
they also decreased from 36.9  8 20.7 to 31.5  8 16.5 IU/l 
in patients treated with sub-therapeutic CPAP (differ-
ence between mean changes –3.4, 95% CI –7.8 to 1.0 IU/l, 
p = 0.13 between groups). The blood levels of AST did not 
change significantly with therapeutic CPAP (from 29.1 
 8 14.7 to 30.2  8 13.6 IU/l), nor with sub-therapeutic 
CPAP (from 28.2  8 16.2 to 29.5  8 12.6 IU/l; difference 
between mean changes –0.2, 95% CI –3.0 to 2.6 IU/l, p = 
0.87 between groups). Individual changes in ALT are 
shown in  figure 1 , and changes in AST are shown in  fig-
ure 2 .
 When data on ALT and AST were analysed as per the 
protocol, again there was no statistically significant dif-
ference in changes between the therapeutic and sub-ther-
apeutic CPAP groups.
 There was no statistically significant correlation be-
tween ALT levels and ODI (r = 0.17, p = 0.10), BMI (r = 
0.15, p = 0.16) nor between AST levels and ODI (r = 0.16, 
p = 0.13) and BMI (r = 0.13, p = 0.20).
 Measures of Sleepiness 
 Therapeutic CPAP significantly reduced the Epworth 
Sleepiness Scale score compared to the sub-therapeutic 
CPAP group: therapeutic 15.8  8 4.2 to 6.8  8 5.1 and sub-
therapeutic 15.2  8 3.8 to 11.6  8 5.9 (mean difference 
between groups –4.7, 95% CI –6.8 to –2.6, p  ! 0.0001). 
Therapeutic CPAP also significantly improved objective 
sleepiness measured by the Osler test compared to sub-
therapeutic CPAP: therapeutic 17.9  8 13.0 to 26.2  8 12.7 
min and sub-therapeutic 17.5  8 12.9 to 18.5  8 14.2 min 
(mean difference between groups 7.0, 95% CI 1.1 to 13.0 
min, p = 0.019). Compliance with CPAP did not differ 
between the 2 groups ( table 1 ). 
Baseline Baseline
Therapeutic Sub-therapeutic
Follow-up Follow-up
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 Fig. 1. Individual ALT levels at baseline 
and follow-up in the therapeutic CPAP 
group (left panel) and sub-therapeutic 
CPAP group (right panel). Large circles 
and vertical bars are means  8 SD. The 
mean ALT levels decreased significantly 
after 4 weeks of therapeutic and sub-ther-
apeutic CPAP, but there was no statisti-
cal difference in the change between the 
therapeutic and sub-therapeutic CPAP 
groups. 
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 Discussion 
 We present the first data from a randomized con-
trolled trial investigating the effects of CPAP on liver en-
zyme levels in patients with moderate-to-severe OSAS. 
We found that blood aminotransferase levels decreased 
in the group treated for 4 weeks with therapeutic CPAP 
and in the group receiving sub-therapeutic CPAP. This 
decrease in liver enzymes was not different between the 
2 groups, despite clear evidence of a differential effect of 
CPAP, with a clear improvement in both subjective and 
objective sleepiness in patients treated with therapeutic 
CPAP compared with sub-therapeutic CPAP. 
 However, the majority of subjects had liver enzyme 
levels within the normal range (77%), and therefore im-
provements might not have been expected. We therefore 
analysed data from patients with ALT levels above and 
below the upper limit of the normal range separately 
(which is 45 IU/l at our institution) and found, again, no 
significant differences in changes between the therapeu-
tic and sub-therapeutic groups. In addition, in patients 
with ALT values in the normal range ( ! 45 IU/l), levels 
also decreased significantly in both the therapeutic and 
sub-therapeutic groups, indicating that a potential floor 
effect was not a confounder.
 Obesity, insulin resistance and dyslipidaemia have 
been shown to contribute to the development of NAFLD 
 [6, 7] . According to a hypothesis Day and Saksena pub-
lished in 2002  [18] , increased oxidative stress may be an 
additional independent factor which may lead to hepato-
cellular injury and thereby promote the development of 
NAFLD. As OSAS has been associated with insulin resis-
tance  [5] , dyslipidaemia  [4] and increased oxidative stress 
 [19] , it seems reasonable to assume that OSAS might
Table 1. Patient characteristics
Sub-thera-
peutic CPAP
(n = 47)
Therapeutic 
CPAP
(n = 47)
p 
value
Age, years 48.5810.4 48.089.5 0.81
Weight, kg 110.2819.2 115.0824.5 0.30
BMI 34.484.6 35.687.1 0.33
Neck circumference, cm 44.683.0 45.183.9 0.55
Waist/hip circumference ratio 1.0080.05 1.0180.06 0.60
Alcohol intake, g/day 6.387.9 9.0813.3 0.23
Current smoker, % 19.2 21.3 0.80
Ex-smoker, % 53.2 44.7 0.41
Hypertensive, % 25.5 21.3 0.63
Diabetic, % 0.0 2.1 0.32
Oxygen saturation dips >4%,
n/h of sleep 44.4821.5 40.4825.0 0.41
Epworth Sleepiness Scale score
at baseline 15.283.8 15.884.2 0.51
Osler at baseline, min 17.5812.9 17.9813.0 0.87
CPAP compliance, h/night 3.982.5 4.682.1 0.18
Retitrated CPAP pressure following
study, cm H2O 10.281.7 9.981.8 0.51
Values are means 8 SD or simple percentages. 
Baseline BaselineFollow-up Follow-up
Therapeutic Sub-therapeutic
p = 0.25 p = 0.23
p = 0.87
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 Fig. 2. Individual AST levels at baseline 
and follow-up in the therapeutic CPAP 
group (left panel) and sub-therapeutic 
CPAP group (right panel). Large circles 
and vertical bars are means  8 SD. The 
mean AST levels did not change signifi-
cantly after 4 weeks of therapeutic and 
sub-therapeutic CPAP, and there was no 
statistical difference in the change be-
tween the therapeutic and sub-therapeutic 
CPAP groups. 
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be an independent risk factor for the development of 
NAFLD. Consistent with this hypothesis, several obser-
vational studies have suggested a link between OSAS and 
NAFLD, having shown a correlation between markers of 
hypoxia, sleep disordered breathing and blood markers 
of liver function in patients with OSAS  [8, 20, 21] . Inter-
pretation of these associations has been difficult, since 2 
of these studies had either no or an inadequate control 
group  [8, 21]. Additionally, in the study by Tatsumi and 
Saibara  [20] , only serum levels of type III procollagen (a 
marker of latent steatohepatitis), but not aminotransfer-
ases, were associated with average SaO 2 during sleep. 
Furthermore, ALT and AST levels were not different in 
patients with OSAS, compared with well-matched con-
trol subjects without OSAS in the latter study. 
 Only 2 studies have investigated the effect of OSAS 
treatment on serum aminotransferase levels  [9, 10] . In a 
uncontrolled study including 40 patients with moderate-
to-severe OSAS, Chin et al.  [9] found a decrease in AST 
of 5 IU/l after a single night of CPAP treatment, but sur-
prisingly CPAP had no effect on the more sensitive ALT; 
this effect persisted at the 6-month follow-up. Kheiran-
dish-Gozal et al.  [10] recently reported a higher preva-
lence of OSAS among obese children with ‘NAFLD’ 
(which they defined entirely by elevated serum amino-
transferases) compared to obese children without 
‘NAFLD’. In the same study, uncontrolled treatment of 
OSAS with tonsillectomy (and CPAP) improved liver en-
zymes in 76% of children. 
 In contrast to these reports, the findings of our study 
show that CPAP treatment has no beneficial effect on liv-
er enzymes when compared to a sham treatment. The 
decrease in ALT we observed in both the therapeutic and 
the sub-therapeutic CPAP groups seems, therefore, to be 
an effect independent of OSAS treatment. A possible ex-
planation for the improved ALT levels may be a non-spe-
cific placebo effect, or the well-known fact that patients 
alter their behaviour when they enter a study (e.g. they are 
more compliant with a prescribed medication or follow a 
healthier lifestyle), which may bias the outcome in an un-
controlled study  [22, 23] . It is possible that patients in our 
study also changed their lifestyle during the trial (e.g. re-
duced alcohol consumption, avoided foods rich in calo-
ries or fat, began to exercise), which may explain the de-
creased levels of ALT that we found after 4 weeks of both 
therapeutic and sub-therapeutic CPAP. That only ALT 
decreased and not AST may be explained by the fact that 
ALT is more specific for liver disease (especially NAFLD) 
 [24, 25] and falls in response to improvements in lifestyle 
 [26] .
 At this point it must be mentioned that the gold stan-
dard for the diagnosis of NAFLD would be a liver biopsy. 
As liver enzymes are not specific markers of liver func-
tion in NAFLD, it may be difficult to investigate the true 
relationship between OSAS and NAFLD without liver bi-
opsy. Therefore, further randomized controlled studies 
including carefully selected patients with histologically 
proven NAFLD and OSAS would be needed to accurate-
ly define this potential relationship.
 In conclusion, this double-blind randomized con-
trolled trial has shown no extra improvement in liver 
function (measured by aminotransferases) in patients 
with symptomatic OSAS following active CPAP treat-
ment for 1 month, when compared to sub-therapeutic 
CPAP, despite a clear differential improvement in both 
subjective and objective sleepiness. 
 The reasons for this similar improvement in both 
groups are not clear, but may be due to the fact that pa-
tients behave differently when entering a clinical trial and 
thereby producing non-specific effects. Therefore, CPAP 
does not seem to improve liver function in a typical co-
hort of OSAS patients.
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